Benetic Biopharma shares are trading higher after the company announced it received FDA clearance of the IND for BB-301 for the treatment of Oculopharyngeal Muscular Dystrophy.
Portfolio Pulse from Benzinga Newsdesk
Benetic Biopharma received FDA clearance for the IND of BB-301, a treatment for Oculopharyngeal Muscular Dystrophy, leading to higher trading of its shares.

June 26, 2023 | 12:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Benetic Biopharma's stock price is likely to increase in the short term due to FDA clearance of BB-301 for the treatment of Oculopharyngeal Muscular Dystrophy.
The FDA clearance of BB-301 for the treatment of Oculopharyngeal Muscular Dystrophy is a significant milestone for Benetic Biopharma. This approval is likely to boost investor confidence in the company's product pipeline and lead to increased demand for its shares, resulting in a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100